Pt DP severe kyphoscoliosis (osteoporosis) due to long term steroid use

Date: 26 November 2013

These pictures show remarkable curvature of the spine as a result of collapse of the vertebral bodies of the thoracic vertebrae. This is a gross example of steroid-induced osteoporosis. The dose was not large in the last 10 years, typically 5-10mg daily, but multiple high dose courses and slow tapering lead to this outcome.

Her corticosteroid warning card is also demonstrated, as additional steroids are required for any significant illness or surgery, as her adrenal glands had completely atrophied.
 

Kindly supplied by Prof David Denning, South Manchester University Hospitals NHS Trust, Manchester UK

(© Fungal Research Trust)

Copyright:

Kindly supplied by Prof David Denning, South Manchester University Hospitals NHS Trust, Manchester UK

Notes:


Images library

Showing 10 posts of 2574 posts found.
  • Title

    Legend

  • Patient with chronic productive cough, chest pain and ABPA, unable to take itraconazole or nebulised amphotericin B. Smokes at least 40 roll up cigarettes a day.

    Nicotine stained fingers - image 1, Nicotine stained fingers - image 2

  • The chemical structure of the novel arylamidine T-2307

    T2307

  • Laryngeal aspergillosis, probably related to inhaled corticosteroids.

    Image A., Image B., Image C., Image D.

  • VL-2397 (formerly known as ASP2397) is a novel antifungal drug initially developed by our partner, Astellas Pharma. This drug was isolated from a leaf litter fungus Acremonium species collected in a Malaysian national park. Astellas presented two posters at the 2014 ICAAC meeting which described the in vitro and the in vivo antifungal activities of this drug. The differentiating attributes from the preclinical data of VL-2397 include:

    • A novel mechanism of action, with a potential to be complementary or synergistic with the existing classes of antifungals.
    • Rapid fungal cell kill activity demonstrated in preclinical models, which was faster than marketed antifungals.
    • Activity against azole-resistant fungal species.
    • Low propensity for P450 drug-drug interactions.

    VL-2397 (ASP2397)

  • SCY-078, new orally available beta-1,3-d-glucan synthase inhibitor, Formely MK-3118.

    SCY-078, new orally available beta-1,3-d-glucan synthase inhibitor

  • Biafungin acetate, a new echinocandin

    Biafungin acetate, a new echinocandin

  • Pt DSM Community acquired primary Aspergillus pneumonia. Two x-rays taken on 02/02/2010 then 05/03/2010

    Pt DSM, Community acquired Aspergillus pneumonia 02/02/2010, Pt DSM, Community acquired Aspergillus pneumonia 02/02/2010